RecruitingPhase 4NCT06611696
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chiba University
- Principal Investigator
- Masayoshi Harigai, MD, PhDInternational University of Health and Welfare
- Intervention
- Avacopan, prednisolone and rituximab(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (22)
- Fujita Health University Hospital, Toyoake, Aichi-ken, Japan
- Asahi General Hospital, Asahi, Chiba, Japan
- Chiba Aoba Municipal Hospital, Chiba, Chiba, Japan
- Chiba University, Chiba, Chiba, Japan
- Chiba Rosai Hospital, Ichihara, Chiba, Japan
- Kameda Medical Centre, Kamogawa, Chiba, Japan
- International University of Health and Welfare, Narita, Chiba, Japan
- Japanese Red Cross Narita Hospital, Narita, Chiba, Japan
- Gunma University, Maebashi, Gunma, Japan
- Kagawa University, Hiragi, Kagawa-ken, Japan
- St.Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
- Tohoku Univerisity, Sendai, Miyagi, Japan
- Nagasaki University, Nagasaki, Nagasaki, Japan
- Okayama University, Okayama, Okayama-ken, Japan
- Kitano Hospital, Osaka, Osaka, Japan
- +7 more locations on ClinicalTrials.gov
Collaborators
Kissei Pharmaceutical Co., Ltd. · International University of Health and Welfare
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06611696 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →